Study wrapper · #974
CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
Jacobsen JM, Halling JF, Blom I, et al. Nature metabolism. 2025.
DOI: 10.1038/s42255-025-01324-8PubMed: 40629149
Editor's note
A rodent mechanistic study attributing roughly one-third of CagriSema's weight-loss effect to blunted metabolic adaptation rather than reduced intake alone. Findings are in rats and should not be extrapolated directly to humans. Relevant mechanistic context for both tracked peptides.
Plain-language abstract
In rats, the cagrilintide-semaglutide combination was associated with weight loss driven mostly by reduced food intake plus preserved energy expenditure.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026